Proxy Results (Form 8-K)

Item 5.07. Submission of Matters to a Vote of Security Holders.

On September 24, 2025, Cadrenal Therapeutics, Inc., a Delaware corporation (the "Company"), held its 2025 annual meeting of stockholders (the "2025 Annual Meeting") at which the Company's stockholders voted on the following two (2) proposals and cast their votes as described below. These matters are described in detail in the definitive proxy statement on Schedule 14A for the 2025 Annual Meeting filed with the Securities and Exchage Commission on July 31, 2025 (the "Proxy Statement"). As of July 28, 2025, the record date of the 2025 Annual Meeting, there were 2,046,854 shares of Common Stock issued and outstanding and entitled to vote at the 2025 Annual Meeting. Present in person or by proxy at the 2025 Annual Meeting were 1,284,746 shares of Common Stock, which constituted a quorum.

The final voting results for each item of business voted upon at the 2025 Annual Meeting, as described in the Proxy Statement, is set forth below.

Proposal 1. Election of Directors Proposal.

The following individual was elected as a Class III director, to serve until the Company's 2028 annual meeting of stockholders and until his successor has been duly elected and qualified with the following votes:

Proposal 2. Auditor Ratification Proposal.

The stockholders ratified and approved the appointment of WithumSmith+Brown, P.C. as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025 based on the votes listed below: